These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10878433)

  • 1. The usefulness of ratios for allocation decisions: the case of stroke.
    Ament A; Evers S; Baltussen R
    Cerebrovasc Dis; 2000; 10(4):283-8. PubMed ID: 10878433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness analysis: a review.
    Rutigliano MJ
    Neurosurgery; 1995 Sep; 37(3):436-43; discussion 443-4. PubMed ID: 7501108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
    Dolan P; Edlin R
    J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The usefulness of average cost-effective ratios.
    Laska EM; Meisner M; Siegel C
    Health Econ; 1997; 6(5):497-504. PubMed ID: 9353650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving value measurement in cost-effectiveness analysis.
    Ubel PA; Nord E; Gold M; Menzel P; Prades JL; Richardson J
    Med Care; 2000 Sep; 38(9):892-901. PubMed ID: 10982111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economics, QALYs and medical ethics: a practical agenda?
    Robinson R
    Health Care Anal; 1995 Aug; 3(3):229-32. PubMed ID: 10151643
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness in orthopedics: providing essential information to both physicians and health care policy makers for appropriate allocation of medical resources.
    Dougherty CP; Howard T
    Sports Med Arthrosc Rev; 2013 Sep; 21(3):166-8. PubMed ID: 23924749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?
    Cadilhac DA; Carter R; Thrift AG; Dewey HM
    Stroke; 2012 May; 43(5):1370-5. PubMed ID: 22363058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternatives to the QALY measure for economic evaluations.
    Gafni A
    Support Care Cancer; 1997 Mar; 5(2):105-11. PubMed ID: 9069609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life after stroke a comprehensive review.
    Tengs TO; Yu M; Luistro E
    Stroke; 2001 Apr; 32(4):964-72. PubMed ID: 11283398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
    Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
    Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
    [No Abstract]   [Full Text] [Related]  

  • 17. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women.
    Wong IO; Tsang JW; Cowling BJ; Leung GM
    Cancer; 2012 Sep; 118(18):4394-403. PubMed ID: 22359352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.